Colorado-based Americann Inc. has announced a partnership with the Veterans Health and Cannabis Citizen Science Study in Massachusetts to research how cannabis can help veterans.
All veterans nationwide are welcome to participate in the study which is led by Cannabis Community Care and Research Network (C3RN) and Umass Dartmouth Charlton College of Business in collaboration with Veterans Alternative Healing.
“We are proud to be a partner of this important research with C3RN and Veterans Alternative Healing,” said Americann CEO Tim Keogh. “These organizations are doing incredible work to remove the stigma around medical cannabis and increase education and access for all, especially our veterans. We look forward to seeing what this study finds and how it can be helpful to veterans.”
The goal of the study is to gain a better understanding of veterans’ health status, medications, treatment regimens, and current cannabis use as well as issues related to their quality of life, insurance access, service history, and demographics.
Participants will be able to view their results and compare them with others who take the survey. Veterans involved in the study will also receive discounts at partner dispensaries in Massachusetts.
The first event of the six-part veterans study commenced in Boston on March 3 at the Cannabis Advancement Conference which was designed to eliminate the stigma behind cannabis.
The second event is scheduled to take place on April 18 in Holyoke, Massachusetts where preliminary data from the veterans study will be presented. The primary focus of the day will be social equity in the cannabis industry.
“Cannabis has the potential to benefit thousands of veterans, “ said C3RN CEO, Dr. Marion McNabb. “Our research will help us further understand the medical uses of cannabis as a treatment for many conditions veterans suffer from, including Chronic pain, PTSD, anxiety and depression.”
Americann, which is currently developing a one-million-square-foot cultivation and processing facility in Freetown, previously conducted a survey in September of 2018 that found that 73 percent of its preferred partner, BASK’s patients use cannabis to reduce the use of unwanted prescriptions.
